课题基金 / 基金详情

Efficacy of Varenicline for Smokless Tobacco Use in India

Efficacy of Varenicline for Smokless Tobacco Use in India
伐尼克兰在印度无烟烟草使用中的功效
批准号:
8051826
负责人:
Robert A Schnoll
金额:
$16.81万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-04-01 至 2014-03-31

项目摘要

项目成果

Robert A Schnoll的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):在美国,无烟烟草的使用率低于吸烟。然而,在过去的几年里,烟草率一直保持不变,烟草公司最近推出了新的无烟烟草产品,作为戒烟辅助手段或作为吸烟的替代品,因为室内公共场所禁止吸烟。相比之下,印度无烟烟草使用率为20%。无烟烟草是致癌物质,在印度每年导致约10,000人死于口腔癌。不幸的是,印度针对无烟烟草使用者的干预试验非常少。在美国,尼古丁替代疗法(NRT)和安非他酮的临床试验结果为零。到目前为止,还没有试验评估FDA批准的新的选择性1422神经元烟碱乙酰胆碱受体部分激动剂varenicline用于无烟烟草用途。因此,拟议的国际合作研究将提高新德里全印度医学研究所(NDDTC)国家药物依赖治疗中心(NDDTC)的研究能力,并在新德里NDDTC的250名无烟烟草使用者中进行Varenicline对无烟烟草依赖的随机安慰剂对照试验。这项试验的主要目的是:1)提高NDDTC的研究能力(即,培训和监督AIIMS工作人员通过药物治疗、数据收集和管理程序以及参与者跟踪系统执行行为咨询协议);2)评估varenicline在提高治疗结束时生化确认的7天点无烟烟草流行率方面的有效性;以及2)评估varenicline治疗后复发和恢复的纵向模式。这项试验还将探索:1)作为varenicline效应机制的无烟烟草戒断症状、渴求、情感和享乐效应的变化;以及2)与无烟烟草有关的变量(例如,无烟烟草的持续时间和类型)、心理变量(例如,抑郁)和人口统计变量(例如,性别)对varenicline的反应的作用,以确定哪些人最有可能从varenicline对无烟烟草的依赖中受益。我们之所以在印度进行这项临床试验,是因为:1)无烟烟草的使用在印度是一个严重的公共卫生问题;2)印度尚未进行过无烟烟草使用的药物疗法试验;3)招募参与者将具有成本效益;4)我们可以评估各种不同的VARENICLINE效应的调节因素(例如,性别)。这项研究的结果可能支持R01试验,以评估长期治疗效果和其他目标,如成本效益和向政策制定者和提供者传播结果的机制。这项拟议的研究还可能为美国无烟烟草使用者提供重要信息,因为:1)美国无烟烟草的使用最近保持不变,并可能在未来几年增加;2)NRT和安非他酮对无烟烟草依赖无效;3)varenicline尚未被评估为治疗无烟烟草使用的方法。 与公共健康相关:无烟烟草在美国的使用率约为3%,远远低于吸烟。然而,在过去的几年里,烟草率一直保持不变,烟草公司最近推出了新的无烟烟草产品,作为戒烟辅助手段或作为吸烟的替代品,因为室内公共场所禁止吸烟。相比之下,印度无烟烟草使用率为20%。到目前为止,在美国的试验中还没有药物疗法证明对无烟烟草使用有效,印度还没有进行无烟烟草使用的药物治疗试验,也没有临床试验评估FDA批准的用于无烟烟草使用的新药varenicline。因此,拟议的国际合作研究将提高新德里全印度医学研究所(NDDTC)国家药物依赖治疗中心(NDDTC)的研究能力,并在新德里NDDTC进行Varenicline无烟烟草依赖的随机安慰剂对照试验。这项试验的结果将填补实证文献中的几个重要空白,解决印度和美国的重大公共卫生问题,并促进印度的其他研究。
英文摘要
DESCRIPTION (provided by applicant): The prevalence of smokeless tobacco use in the US is low vs. cigarette smoking. Yet, rates have remained constant over the past few years, and tobacco companies recently launched new smokeless tobacco products as smoking cessation aids or as alternatives to smoking given bans on smoking in indoor public places. In contrast, the rate of smokeless tobacco use in India is 20%. Smokeless tobacco is carcinogenic and responsible for ~10,000 deaths/year from oral cancer in India. Unfortunately, there have been remarkably few intervention trials in India for smokeless tobacco users. In the US, clinical trials of nicotine replacement therapies (NRTs) and bupropion have yielded null findings. To date, no trial has evaluated the new FDA- approved selective 1422 neuronal nicotinic acetylcholine receptor partial agonist, varenicline, for smokeless tobacco use. Thus, the proposed international collaborative study would enhance research capacity at the National Drug Dependence Treatment Center (NDDTC) at the All India Institute of Medicine in New Delhi and conduct a randomized placebo-controlled trial of varenicline for smokeless tobacco dependence with 250 smokeless tobacco users at the NDDTC in New Delhi. The primary aims of this trial are to: 1) enhance research capacity at the NDDTC (i.e., train and supervise AIIMS staff to implement the behavioral counseling protocol with pharmacotherapy, data collection and management procedures, and participant tracking systems); 2) assess the efficacy of varenicline for increasing biochemically confirmed 7-day point prevalence smokeless tobacco quit rates at the end-of-treatment; and 2) assess longitudinal patterns of relapse and recovery following treatment with varenicline. This trial will also explore: 1) changes in withdrawal symptoms, craving, affect, and hedonic effects of smokeless tobacco as mechanisms of varenicline effects; and 2) the role of smokeless tobacco-related (e.g., duration and type of smokeless tobacco), psychological (e.g., depression), and demographic (e.g., gender) variables on response to varenicline to identify those most likely to benefit from varenicline for smokeless tobacco dependence. We propose this clinical trial in India since: 1) smokeless tobacco use is a substantial public health problem in India; 2) no pharmacotherapy trials for smokeless tobacco use have been conducted in India; 3) participant recruitment will be cost-effective; and 4) we can assess a broad range of moderators of varenicline effects (e.g., gender). The results from this study may support an R01 trial to evaluate long-term treatment effects and additional aims such as cost-effectiveness and mechanisms for the dissemination of results to policy-makers and providers. The proposed study may also yield important information for US smokeless tobacco users since: 1) smokeless tobacco use in the US has remained constant recently and may increase in the coming years; 2) NRT and bupropion are ineffective for smokeless tobacco dependence; and 3) varenicline has not been evaluated as a treatment for smokeless tobacco use. PUBLIC HEALTH RELEVANCE: The prevalence of smokeless tobacco use in the US is ~3%, which is far lower than for cigarette smoking. Yet, rates have remained constant over the past few years, and tobacco companies recently launched new smokeless tobacco products as smoking cessation aids or as alternatives to smoking given bans on smoking in indoor public places. In contrast, the rate of smokeless tobacco use in India is 20%. To date, no pharmacotherapy has demonstrated efficacy for smokeless tobacco use in US trials, no pharmacotherapy trials for smokeless tobacco use have been conducted in India, and no clinical trial has evaluated the new FDA- approved medication for tobacco smoke, varenicline, for smokeless tobacco use. Thus, the proposed international collaborative study would enhance research capacity at the National Drug Dependence Treatment Center (NDDTC) at the All India Institute of Medicine in New Delhi and conduct a randomized placebo- controlled trial of varenicline for smokeless tobacco dependence at the NDDTC in New Delhi. The results from this trial will fill several important gaps in the empirical literature, address significant public health concerns for India and the US, and facilitate additional research studies in India.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Patient-Oriented Research Mentoring Program in Tobacco Dependence Research
  • 批准号:
    10094212
  • 项目类别:
  • 资助金额:
    $18.7万
  • 财政年份:
    2018
  • 负责人:
    Robert A Schnoll
  • 依托单位:
A Mentoring Program in Patient-Oriented Tobacco Dependence and Implementation Science Research
  • 批准号:
    10700361
  • 项目类别:
  • 资助金额:
    $19.75万
  • 财政年份:
    2018
  • 负责人:
    Robert A Schnoll
  • 依托单位:
A Patient-Oriented Research Mentoring Program in Tobacco Dependence Research
  • 批准号:
    10350574
  • 项目类别:
  • 资助金额:
    $18.7万
  • 财政年份:
    2018
  • 负责人:
    Robert A Schnoll
  • 依托单位:
Testing an Organizational Change Model to Address Smoking in Mental Healthcare
  • 批准号:
    9886075
  • 项目类别:
  • 资助金额:
    $63.77万
  • 财政年份:
    2016
  • 负责人:
    Robert A Schnoll
  • 依托单位:
海外基金